Android app on Google Play

Cell Therapeutics Inc. (CTIC) Reports In-Line Q4 Loss of $0.20/Sh

February 28, 2013 5:35 PM EST Send to a Friend
Get Alerts CTIC Hot Sheet
Trade CTIC Now!
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20).

For 2013, loss from operations is expected to be approximately $60 to $65 million, excluding non-cash stock-based compensation expense.

For earnings history and earnings-related data on Cell Therapeutics Inc. (CTIC) click here.

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment